| dc.contributor.author |
Hamam, Rola N. |
|
| dc.contributor.author |
Barikian, Anita W. |
|
| dc.contributor.author |
Antonios, Rafic S. |
|
| dc.contributor.author |
Abdulaal, Marwan R. |
|
| dc.contributor.author |
Alameddine, Ramzi M. |
|
| dc.contributor.author |
El Mollayess, Georges |
|
| dc.contributor.author |
Mansour, Ahmad M. |
|
| dc.date.accessioned |
2022-10-14T13:29:33Z |
|
| dc.date.available |
2022-10-14T13:29:33Z |
|
| dc.date.copyright |
2016 |
en_US |
| dc.date.issued |
2022-10-14 |
|
| dc.identifier.issn |
0927-3948 |
en_US |
| dc.identifier.uri |
http://hdl.handle.net/10725/14065 |
|
| dc.description.abstract |
Purpose: To evaluate the short-term efficacy of intravitreal adalimumab (IVA) for the treatment of eyes with active noninfectious uveitis.
Methods: Consecutive eyes with active noninfectious uveitis were injected with IVA at 0, 2, then every 4 weeks for total of 26 weeks.
Results: Six out of 7 patients (12 of 13 eyes) completed 26 weeks of treatment. One patient (1 eye) failed treatment. Seven out of 12 eyes had improvement of ≥2 ETDRS lines. Three out of three eyes had resolution of anterior chamber cells. And 9 of 10 eyes with vitreous haze had zero haze at 26 weeks. Five out of 8 eyes with macular edema had complete resolution. Median fluorescein angiography score improved from 14 to 4 on last follow-up.
Conclusions: IVA was effective in controlling the inflammation, decreasing the macular edema, and improving the best corrected visual acuity in the majority of eyes in this series. |
en_US |
| dc.language.iso |
en |
en_US |
| dc.title |
Intravitreal adalimumab in active noninfectious uveitis |
en_US |
| dc.type |
Article |
en_US |
| dc.description.version |
Published |
en_US |
| dc.title.subtitle |
a pilot study |
en_US |
| dc.author.school |
SOM |
en_US |
| dc.author.idnumber |
201805227 |
en_US |
| dc.author.department |
N/A |
en_US |
| dc.relation.journal |
Ocular Immunology and Inflammation |
en_US |
| dc.journal.volume |
24 |
en_US |
| dc.journal.issue |
3 |
en_US |
| dc.article.pages |
319-326 |
en_US |
| dc.keywords |
Adalimumab |
en_US |
| dc.keywords |
Intravitreal adalimumab |
en_US |
| dc.keywords |
Noninfectious uveitis |
en_US |
| dc.keywords |
Uveitis treatment |
en_US |
| dc.identifier.doi |
https://doi.org/10.3109/09273948.2014.990041 |
en_US |
| dc.identifier.ctation |
Hamam, R. N., Barikian, A. W., Antonios, R. S., Abdulaal, M. R., Alameddine, R. M., El Mollayess, G., & Mansour, A. M. (2016). Intravitreal adalimumab in active noninfectious uveitis: a pilot study. Ocular immunology and inflammation, 24(3), 319-326. |
en_US |
| dc.author.email |
georges.elmollayess@lau.edu.lb |
en_US |
| dc.identifier.tou |
http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php |
en_US |
| dc.identifier.url |
https://www.tandfonline.com/doi/full/10.3109/09273948.2014.990041 |
en_US |
| dc.author.affiliation |
Lebanese American University |
en_US |